September 13, 2023 04:15 PM EDTUpdated September 14, 08:11 AM

FDA adcomm votes in favor of Alnylam's new indication for Onpattro

Zachary Brennan

Senior Editor

The FDA’s Cardiovascular and Renal Drugs Advisory Committee on Wednesday voted 9-3 in favor of Alnylam Pharmaceuticals’ Onpattro (patisiran) on whether its benefits outweigh its …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

FDA adcomm votes in favor of Alnylam's new indication for Onpattro

Zachary Brennan

Senior Editor

Sign up to read this article for free.

Patient dies in Neurogene's Rett syndrome study

Lilly's board undergoes more changes; Merck strategy chief joins Roger Perlmutter at Eikon

Surrounded by AI bio giants, tiny startup Nabla Bio makes de novo antibodies look more like drugs

Microsoft-backed Enveda raises $130M for drugs in I&I, obesity and other areas

Halozyme withdraws Evotec acquisition proposal after biotech is 'unwilling to engage'

Are programs with compounded GLP-1s safe for your population?

FDA ad­comm votes in fa­vor of Al­ny­lam's new in­di­ca­tion for On­pat­tro

Zachary Brennan

Senior Editor

Sign up to read this article for free.

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

Lil­ly's board un­der­goes more changes; Mer­ck strat­e­gy chief joins Roger Perl­mut­ter at Eikon

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs

Mi­crosoft-backed Enve­da rais­es $130M for drugs in I&I, obe­si­ty and oth­er ar­eas

Halozyme with­draws Evotec ac­qui­si­tion pro­pos­al af­ter biotech is 'un­will­ing to en­gage'

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

FDA adcomm votes in favor of Alnylam's new indication for Onpattro

Patient dies in Neurogene's Rett syndrome study

Lilly's board undergoes more changes; Merck strategy chief joins Roger Perlmutter at Eikon

Surrounded by AI bio giants, tiny startup Nabla Bio makes de novo antibodies look more like drugs

Microsoft-backed Enveda raises $130M for drugs in I&I, obesity and other areas

Halozyme withdraws Evotec acquisition proposal after biotech is 'unwilling to engage'

Are programs with compounded GLP-1s safe for your population?